2 DOSAGE AND ADMINISTRATION
)Tj 0 Tc T* ( )Tj 0.0007 Tc -0.0007 Tw T* [(Across all trials, VIAGRA im)8.5 (proved the erections)1 ( of 43% of radical prostatectom)8.5 (y patients )]TJ T* [(com)8.4 (p)0.6 (ared to 15% on placebo. )]TJ 0 Tc 0 Tw T* ( )Tj 0.0007 Tc -0.0007 Tw T* [(Subgroup analyses of responses to a global im)8.5 (provem)8.5 (ent question in patients with psychogenic )]TJ T* (etiology in two fixed-dose studies \(total n=179\) )Tj 0.0008 Tc -0.0008 Tw 19.345 0 Td (and two titration studies \(total n=149\) showed )Tj 0.0005 Tc -0.0005 Tw -19.345 -1.165 Td [(84% of VIAGRA patients reported im)8.3 (provem)8.3 (e)-0.7 (nt in)]TJ 0.0006 Tc -0.0006 Tw 20.61 0 Td [( erections com)8.4 (p)0.6 (ared with 26% of placebo. )]TJ 0.0005 Tc -0.0005 Tw -20.61 -1.165 Td [(The changes from)8.3 ( baseline in scoring on the two end point questions \(frequency of succe\ ssful )]TJ 0.0009 Tc -0.0009 Tw T* [(penetration during sexual activity and m)8.7 (aintenance of erections after penetration\) were highly )]TJ 0.0005 Tc -0.0005 Tw 0 -1.18 TD (statistically significantly in favor of VIAGRA)Tj /TT1 1 Tf 0 Tc 0 Tw 18.435 0 Td (.
- Sildenafil white is sometimes called the "blue pill" in popular culture.
- It remains one of the most prescribed medications for ED worldwide.
- Some individuals purchase sildenafil white without a prescription, which can be risky.
- Derived from a scientific discovery initially aimed at heart treatment.
- Viagra was the first brand to market sildenafil for ED.
- The medication can cause side effects like dizziness and upset stomach.
- Elderly patients should be cautious due to increased risk of side effects.
- Regular medical check-ups are recommended for long-term sildenafil users.
- Lifestyle changes, such as exercise and diet, can enhance treatment results.
- The medication is typically taken on an empty stomach for quicker effect.
- Research continues into new formulations and delivery methods for sildenafil
)Tj /TT0 1 Tf 0.0005 Tc -0.0005 Tw ( Diary data in two of the studies \(n=178\) showed )Tj -18.435 -1.165 Td [(rates of successful intercourse per attem)8.3 (p)0.5 (t of 70% for VIAGRA and 29% for placebo. )]TJ 0 Tc 0 Tw 0 -1.165 TD ( )Tj 0.0005 Tc -0.0005 Tw T* [(A review of population subgroups dem)8.3 (onstrated)]TJ 0.0007 Tc -0.0007 Tw ( efficacy regardless of baseline severity, )Tj 0.0003 Tc -0.0003 Tw T* (etiology, race and age.
Sildenafil Dosage
What should I do if I miss a dose of sildenafil?
What does Teva sildenafil do?
VIAGRA was effective in )Tj 0.0006 Tc -0.0006 Tw 20.005 0 Td (a broad range of ED patients, including those )Tj -20.005 -1.165 Td (with a history of coronary artery sildenafil citrate tablets 150 mg disease, hype)Tj 0.0011 Tc -0.0011 Tw 18.58 0 Td (rtension, other cardiac disease, peripheral vascular )Tj 0.0008 Tc -0.0008 Tw -18.58 -1.165 Td [(disease, diabetes m)8.6 (ellitus, depression, coronary artery bypass graft \(CABG\), radical )]TJ T* [(prostatectom)8.6 (y, transurethral resection of the prostate \(TURP\) and spinal cord inju\ ry, and in )]TJ 0.001 Tc -0.001 Tw T* (patients taking antidepressants/antipsychotics and antihypertensives/diu\ retics.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Viagra Generic | 25mg | 180 + 6 Pills | 154.93€ 147.55€ | |
| Viagra Generic | 200mg | 60 + 4 Pills | 125.19€ 119.23€ | |
| Kamagra | 100mg | 60 + 4 Pills | 201.34€ 191.75€ | |
| Kamagra Oral Jelly | 100mg | 21 Sachets | 95.92€ 91.35€ | |
| Viagra Generic | 150mg | 20 Pills | 55.02€ 52.40€ | |
| Viagra Generic | 200mg | 10 Pills | 40.96€ 39.01€ | |
| Kamagra Soft Tabs | 100mg | 272 + 12 Pills | 593.42€ 565.16€ | |
| Kamagra Polo | 100mg | 32 Pills | 125.88€ 119.89€ | |
| Kamagra | 100mg | 120 + 6 Pills | 330.74€ 314.99€ | |
| Kamagra | 100mg | 180 + 6 Pills | 436.79€ 415.99€ | |
| Viagra Generic | 25mg | 120 + 6 Pills | 125.56€ 119.58€ | |
| Viagra Generic | 25mg | 270 + 8 Pills | 184.26€ 175.49€ | |
| Viagra Generic | 25mg | 20 Pills | 37.74€ 35.94€ | |
| Kamagra Soft Tabs | 100mg | 32 Pills | 120.11€ 114.39€ | |
| Kamagra Polo | 100mg | 60 + 4 Pills | 189.39€ 180.37€ | |
| Viagra Generic | 150mg | 180 + 10 Pills | 236.46€ 225.20€ | |
| Kamagra Soft Tabs | 100mg | 120 + 6 Pills | 311.78€ 296.93€ |
)Tj 0 Tc 0 Tw T* ( )Tj 0.0004 Tc -0.0004 Tw T* (Analysis of the safety database showed no appa)Tj 0.0006 Tc -0.0006 Tw (rent difference in the side effect profile in )Tj 0.0004 Tc -0.0004 Tw T* (patients taking VIAGRA with and without anti)Tj 0.0008 Tc -0.0008 Tw 18.795 0 Td [(hypertensive m)8.6 (edication. This analysis was )]TJ 0.0006 Tc -0.0006 Tw -18.795 -1.165 Td [(perform)8.4 (e)-0.6 (d retrospectively, and was not powered to )-1.2 (detect any pre-specified difference in adverse )]TJ 0.001 Tc 0 Tw T* (reactions.
Detection in biological fluids
Percentage of Patients Reporting )Tj 0.0011 Tc 0.0003 Tw 2.568 -1.159 Td [(an Im)8.4 (provem)8.4 (e)2.3 (nt in Erections. )]TJ 0 Tc 0 sildenafil 200 mg Tw 12 0 0 12 59.8642 405.7628 Tm ( )Tj 0.0006 Tc -0.0006 Tw 0.3 -1.165 Td (The patients in studies had varying degrees of ED. One-third to one-half\ of the subjects in these )Tj 0.0009 Tc -0.0009 Tw 0 -1.165 TD [(studies reported successful intercourse at leas)-2.2 (t once during a 4-week, treatm)8.7 (ent-free run-in )]TJ 0.0007 Tc 0 Tw T* (period. )Tj 0 Tc -0.3 -1.165 Td ( )Tj 0.0007 Tc -0.0007 Tw 0.3 -1.165 Td [(In m)8.5 (any of)3.7 ( the studies, of)3.7 ( both f)3.7 (i)-1.5 (xed dose and titration designs, daily diaries were kept by )]TJ 0.0008 Tc -0.0008 Tw T* (patients. In these studies, involving about 1600 patie)Tj 0.0006 Tc -0.0006 Tw 21.065 0 Td (nts, analyses of patient diaries showed no )Tj 0.0003 Tc -0.0003 Tw -21.065 -1.165 Td [(effect of VIAGRA on rates of attem)8.1 (pted interc)]TJ 0.0008 Tc -0.0008 Tw 18.69 0 Td (ourse \(about 2 per week\), but there was clear )Tj 0.0009 Tc -0.0009 Tw -18.69 -1.165 Td [(treatm)8.7 (ent-related im)8.7 (provem)8.7 (ent in sexual function: per patient weekly success rates averaged 1.3 )]TJ 0 Tc 0 Tw T* [(on 50-100 m)7.8 (g of VIAGRA vs 0.4 on placebo; si)]TJ 0.001 Tc -0.001 Tw 19.27 0 Td [(m)8.8 (ilarly, group m)8.8 (ean success rates \(total )]TJ 0.0006 Tc -0.0006 Tw -19.27 -1.165 Td [(successes divided by total attem)8.4 (p)0.6 (ts\) were about 66% on VIAGRA vs about 20% on placebo.
Teva sildenafil pills are white, not blue
)]TJ 0 Tc 0 Tw T* ( )Tj 0.0005 Tc -0.0005 Tw T* [(During 3 to 6 m)8.3 (onths of double-blind treatm)8.3 (e)-0.7 (nt or)]TJ 0.0008 Tc -0.0008 Tw 20.12 0 Td [( longer-term)8.6 ( \(1 year\), open-label studies, few )]TJ -20.12 -1.165 Td [(patients withdrew from)8.6 ( active treatm)8.6 (ent for any )]TJ 0.0005 Tc -0.0005 Tw 19.37 0 Td (reason, including lack of effectiveness. At the )Tj 0.0007 Tc -0.0007 Tw -19.37 -1.165 Td [(end of the long-term)8.5 ( study, 88% of patients re)2.2 (ported that VIAGRA im)8.4 (proved their erections. )]TJ 0 Tc 0 Tw T* ( )Tj 0.0007 Tc -0.0007 Tw T* (Men with untreated ED had relatively low baseline scores for all aspects\ of sexual function )Tj T* [(m)8.4 (easured \(again using a 5-point scale\) in the IIEF.
Kamagra Polo
)Tj 0 Tc T* ( )Tj T* ( )Tj /TT1 1 Tf -0.0013 Tc 0.0013 Tw 0 -1.18 TD [( )-13095 (INDICATION AND USAGE )]TJ /TT0 1 Tf 0.0005 Tc -0.0005 Tw 0 -1.155 TD [(VIAGRA is indicated for the treatm)8.3 (e)-0.7 (nt of erectile dysfunction. )]TJ 0 Tc 0 Tw 0 -1.165 TD ( )Tj T* ( )Tj ET /Artifact <>BDC Q q 1 0 0 1 120.6970062 785.2004395 cm /GS1 gs /Fm0 Do Q EMC /Artifact <>BDC q 1 0 0 1 612 773.2004395 cm /GS1 gs /Fm1 Do Q EMC endstream endobj 382 0 obj <>>>/Resources 385 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 65.791 -7.9 Td (This ) Tj 22.92 0 Td (label ) Tj 26.055 0 Td (may ) Tj 22.71 0 Td (not ) Tj 18.12 0 Td (be ) Tj 14.692 0 Td (the ) Tj 18.023 0 Td (latest ) Tj 29.595 0 Td (approved ) Tj 48.974 0 Td (by ) Tj 14.17 0 Td (FDA.
Warnings & Precautions
What’s the difference between sildenafil and Viagra?
Drug Interactions
) Tj -281.05 -12 Td (For ) Tj 18.96 0 Td (current ) Tj 38.765 0 Td (labeling ) Tj 41.055 0 Td (information, ) Tj 61.25 0 Td (please ) Tj 34.707 0 Td (visit ) Tj 22.299 0 Td ( Tj ET endstream endobj 383 0 obj <>>>/Resources 387 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 0 -7.9 Td ( ) Tj ET endstream endobj 387 0 obj <> endobj 388 0 obj <> endobj 386 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 385 0 obj <> endobj 389 0 obj <> endobj 384 0 obj <>stream /This label may not be the latest approved by FDA.
| Property | Description | Typical Dosage | Appearance | Packaging Type |
|---|---|---|---|---|
| Name | Sildenafil White | 50 mg, 100 mg | White, Round Pills | Blister Pack |
| Chemical Formula | C22H30N6O4S | N/A | N/A | N/A |
| Manufacturer | Example Pharma Co. | N/A | N/A | N/A |
| Storage Conditions | Store in a cool, dry place | N/A | N/A | N/A |
For current labeling information, please visit endstream endobj 381 0 obj <> endobj 376 0 obj <>stream q 1 0 0 1 -8.535767 -1.877228 cm 0 0 612 792 re W n 1 0 0 1 8.535767 1.877228 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.4642 47.6228 Tm ( )Tj 19.25 -0.005 Td (8)Tj 0.0009 Tc -0.0009 Tw -19.25 54.94 Td [(on placebo. In the titration studies \(n=644\) \(with m)8.7 (o)0.9 (st patients eventually receiving 100 m)8.7 (g)0.9 (\), )]TJ 0.0011 Tc -0.0011 Tw sildenafil film tablet 0 -1.165 TD [(results were sim)8.9 (ilar. )]TJ 0 Tc 0 Tw -0.3 -1.165 Td ( )Tj 0.3 -17.655 Td ( )Tj ET q 1 0 0 1 -8.535767 -1.877228 cm 1 g 205.8 524.58 22.86 33.24 re f Q q 1 0 0 1 -8.535767 -1.877228 cm 205.26 524.58 24 33.78 re W n 0.961 w 1 j 1 J 205.8 557.82 22.86 -33.24 re S Q q 1 0 0 1 -8.535767 -1.877228 cm 1 g 262.5 524.58 22.86 87.12 re f Q q 1 0 0 1 -8.535767 -1.877228 cm 261.96 524.58 24 87.66 re W n 0.961 w 1 j 1 J 262.5 611.7 22.86 -87.12 re S Q q 1 0 0 1 -8.535767 -1.877228 cm 1 g 319.2 524.58 22.62 102.24 re f Q q 1 0 0 1 -8.535767 -1.877228 cm 318.66 524.58 23.76 102.78 re W n 0.961 w 1 j 1 J 319.2 626.82 22.62 -102.24 re S Q q 1 0 0 1 -8.535767 -1.877228 cm 1 g 375.66 524.58 22.86 113.34 re f Q q 1 0 0 1 -8.535767 -1.877228 cm 375.12 524.58 24 113.88 re W n 0.961 w 1 j 1 J 375.66 637.92 22.86 -113.34 re S Q q 1 0 0 1 -8.535767 -1.877228 cm 0.06 w 1 j 1 J q 1 0 0 1 189 662.88 cm 0 0 m 0 -138.3 l -2.4 -138.3 m 2.4 -138.3 l -2.4 -110.64 m 2.4 -110.64 l -2.4 -82.98 m 2.4 -82.98 l -2.4 -55.32 m 2.4 -55.32 l -2.4 -27.66 m 2.4 -27.66 l -2.4 0 m 2.4 0 l 0 -138.3 m 226.56 -138.3 l 0 -140.7 m 0 -135.84 l 56.7 -140.7 m 56.7 -135.84 l 113.4 -140.7 m 113.4 -135.84 l 169.86 -140.7 m 169.86 -135.84 l 226.56 -140.7 m 226.56 -135.84 l S Q Q BT /TT1 1 Tf 7.9369 0 0 7.9369 170.1442 520.4828 Tm (0)Tj -0.0119 Tc -0.544 3.485 Td (20)Tj 0 3.485 TD (40)Tj T* (60)Tj T* (80)Tj -0.544 3.485 Td (100)Tj -0.0421 Tc 4.233 -18.884 Td [(P)-40.4 (l)-31.6 (ac)-63.7 (eb)-30.2 (o)]TJ -0.0107 Tc 0.363 -1.3 Td [(n=4)-6.4 (6)1.2 (3)]TJ -0.0027 Tc 6.63 1.3 Td [(VIAG)-18.6 (R)-6.3 (A)]TJ -0.0107 Tc 0.005 Tw 0.544 -1.3 Td (25 mg)Tj 0 Tw -0.03 -1.308 Td [(n=2)-6.4 (1)1.2 (4)]TJ -0.0027 Tc 6.6 2.608 Td [(VIAG)-18.6 (R)-6.3 (A)]TJ -0.0107 Tc 0.005 Tw 0.544 -1.3 Td (50 mg)Tj 0 Tw -0.03 -1.308 Td [(n=3)-6.4 (9)1.2 (1)]TJ -0.0027 Tc 6.63 2.608 Td [(VIAG)-11.1 (R)-13.8 (A)]TJ -0.0109 Tc 0.0052 Tw 0.272 -1.3 Td (100 mg)Tj -0.0107 Tc 0 Tw 0.242 -1.308 Td [(n=3)-6.4 (8)1.2 (0)]TJ -0.0421 Tc 0.0364 Tw -12.927 -1.724 Td [(T)-73.8 (r)-41.7 (eat)-36.4 (m)-25.5 (en)-30.2 (t)-36.4 ( g)-30.2 (r)-41.7 (ou)-30.2 (p)]TJ 0.0019 Tc 0 Tw 0 7.9369 -7.9369 0 155.5642 518.3828 Tm [(Percentage pati)4.8 (ents reporti)4.8 (ng i)4.8 (m)3.3 (proveme)]TJ ET q 1 0 0 1 -8.535767 -1.877228 cm 156.78 520.2 9.18 148.26 re W n 1 0 0 1 8.535767 1.877228 cm BT 0 Tc 0 7.9369 -7.9369 0 155.5642 664.4228 Tm (n)Tj ET Q q 1 0 0 1 -8.535767 -1.877228 cm 1 g 209.4 559.98 28.86 13.68 re f Q BT -0.0119 Tc 7.9369 0 0 7.9369 203.0242 563.5028 Tm [(24)-7.6 (%)]TJ ET q 1 0 0 1 -8.535767 -1.877228 cm 1 g 377.82 638.64 21.9 14.16 re f Q BT 7.9369 0 0 7.9369 371.4442 642.6428 Tm (82%)Tj ET q 1 0 0 1 -8.535767 -1.877228 cm 1 g 322.56 627.54 21.9 14.22 re f Q BT 7.9369 0 0 7.9369 316.1842 631.6028 Tm (74%)Tj ET q 1 0 0 1 -8.535767 -1.877228 cm 1 g 266.34 613.14 21.9 14.16 re f Q BT 7.9369 0 0 7.9369 259.9642 617.1428 Tm [(63)-7.6 (%)]TJ /TT0 1 Tf 0 Tc 12 0 0 12 470.2042 467.0228 Tm ( )Tj 0.0011 Tc 0.0022 Tw 9 0 0 9 63.4642 458.6228 Tm ( )Tj 9 0 Td (Overall treatment p<0.0001 )Tj 0 Tc 0 Tw 12 0 0 12 63.4642 445.1828 Tm ( )Tj 0.0008 Tc 0.0006 Tw 10.98 0 0 10.98 203.9242 432.2228 Tm (Figure 4. Percentage of Patients Reporting )Tj 0.0011 Tc 0.0003 Tw 2.568 -1.159 Td [(an Im)8.4 (provem)8.4 (e)2.3 (nt in Erections. )]TJ 0 Tc 0 sildenafil 200 mg Tw 12 0 0 12 59.8642 405.7628 Tm ( )Tj 0.0006 Tc -0.0006 Tw 0.3 -1.165 Td (The patients in studies had varying degrees of ED. One-third to one-half\ of the subjects in these )Tj 0.0009 Tc -0.0009 Tw 0 -1.165 TD [(studies reported successful intercourse at leas)-2.2 (t once during a 4-week, treatm)8.7 (ent-free run-in )]TJ 0.0007 Tc 0 Tw T* (period. )Tj 0 Tc -0.3 -1.165 Td ( )Tj 0.0007 Tc -0.0007 Tw 0.3 -1.165 Td [(In m)8.5 (any of)3.7 ( the studies, of)3.7 ( both f)3.7 (i)-1.5 (xed dose and titration designs, daily diaries were kept by )]TJ 0.0008 Tc -0.0008 Tw T* (patients. In these studies, involving about 1600 patie)Tj 0.0006 Tc -0.0006 Tw 21.065 0 Td (nts, analyses of patient diaries showed no )Tj 0.0003 Tc -0.0003 Tw -21.065 -1.165 Td [(effect of VIAGRA on rates of attem)8.1 (pted interc)]TJ 0.0008 Tc -0.0008 Tw 18.69 0 Td (ourse \(about 2 per week\), but there was clear )Tj 0.0009 Tc -0.0009 Tw -18.69 -1.165 Td [(treatm)8.7 (ent-related im)8.7 (provem)8.7 (ent in sexual function: per patient weekly success rates averaged 1.3 )]TJ 0 Tc 0 Tw T* [(on 50-100 m)7.8 (g of VIAGRA vs 0.4 on placebo; si)]TJ 0.001 Tc -0.001 Tw 19.27 0 Td [(m)8.8 (ilarly, group m)8.8 (ean success rates \(total )]TJ 0.0006 Tc -0.0006 Tw -19.27 -1.165 Td [(successes divided by total attem)8.4 (p)0.6 (ts\) were about 66% on VIAGRA vs about 20% on placebo.
2.2 Use with Food
)Tj 0 Tc T* ( )Tj 0.0007 Tc -0.0007 Tw T* [(Across all trials, VIAGRA im)8.5 (proved the erections)1 ( of 43% of radical prostatectom)8.5 (y patients )]TJ T* [(com)8.4 (p)0.6 (ared to 15% on placebo. )]TJ 0 Tc 0 Tw T* ( )Tj 0.0007 Tc -0.0007 Tw T* [(Subgroup analyses of responses to a global im)8.5 (provem)8.5 (ent question in patients with psychogenic )]TJ T* (etiology in two fixed-dose studies \(total n=179\) )Tj 0.0008 Tc -0.0008 Tw 19.345 0 Td (and two titration studies \(total n=149\) showed )Tj 0.0005 Tc -0.0005 Tw -19.345 -1.165 Td [(84% of VIAGRA patients reported im)8.3 (provem)8.3 (e)-0.7 (nt in)]TJ 0.0006 Tc -0.0006 Tw 20.61 0 Td [( erections com)8.4 (p)0.6 (ared with 26% of placebo. )]TJ 0.0005 Tc -0.0005 Tw -20.61 -1.165 Td [(The changes from)8.3 ( baseline in scoring on the two end point questions \(frequency of succe\ ssful )]TJ 0.0009 Tc -0.0009 Tw T* [(penetration during sexual activity and m)8.7 (aintenance of erections after penetration\) were highly )]TJ 0.0005 Tc -0.0005 Tw 0 -1.18 TD (statistically significantly in favor of VIAGRA)Tj /TT1 1 Tf 0 Tc 0 Tw 18.435 0 Td (. )Tj /TT0 1 Tf 0.0005 Tc -0.0005 Tw ( Diary data in two of the studies \(n=178\) showed )Tj -18.435 -1.165 Td [(rates of successful intercourse per attem)8.3 (p)0.5 (t of 70% for VIAGRA and 29% for placebo. )]TJ 0 Tc 0 Tw 0 -1.165 TD ( )Tj 0.0005 Tc -0.0005 Tw T* [(A review of population subgroups dem)8.3 (onstrated)]TJ 0.0007 Tc -0.0007 Tw ( efficacy regardless of baseline severity, )Tj 0.0003 Tc -0.0003 Tw T* (etiology, race and age.
How sildenafil is used
VIAGRA was effective in )Tj 0.0006 Tc -0.0006 Tw 20.005 0 Td (a broad range of ED patients, including those )Tj -20.005 -1.165 Td (with a history of coronary artery sildenafil citrate tablets 150 mg disease, hype)Tj 0.0011 Tc -0.0011 Tw 18.58 0 Td (rtension, other cardiac disease, peripheral vascular )Tj 0.0008 Tc -0.0008 Tw -18.58 -1.165 Td [(disease, diabetes m)8.6 (ellitus, depression, coronary artery bypass graft \(CABG\), radical )]TJ T* [(prostatectom)8.6 (y, transurethral resection of the prostate \(TURP\) and spinal cord inju\ ry, and in )]TJ 0.001 Tc -0.001 Tw T* (patients taking antidepressants/antipsychotics and antihypertensives/diu\ retics. )Tj 0 Tc 0 Tw T* ( )Tj 0.0004 Tc -0.0004 Tw T* (Analysis of the safety database showed no appa)Tj 0.0006 Tc -0.0006 Tw (rent difference in the side effect profile in )Tj 0.0004 Tc -0.0004 Tw T* (patients taking VIAGRA with and without anti)Tj 0.0008 Tc -0.0008 Tw 18.795 0 Td [(hypertensive m)8.6 (edication. This analysis was )]TJ 0.0006 Tc -0.0006 Tw -18.795 -1.165 Td [(perform)8.4 (e)-0.6 (d retrospectively, and was not powered to )-1.2 (detect any pre-specified difference in adverse )]TJ 0.001 Tc 0 Tw T* (reactions. )Tj 0 Tc T* ( )Tj T* ( )Tj /TT1 1 Tf -0.0013 Tc 0.0013 Tw 0 -1.18 TD [( )-13095 (INDICATION AND USAGE )]TJ /TT0 1 Tf 0.0005 Tc -0.0005 Tw 0 -1.155 TD [(VIAGRA is indicated for the treatm)8.3 (e)-0.7 (nt of erectile dysfunction. )]TJ 0 Tc 0 Tw 0 -1.165 TD ( )Tj T* ( )Tj ET /Artifact <>BDC Q q 1 0 0 1 120.6970062 785.2004395 cm /GS1 gs /Fm0 Do Q EMC /Artifact <>BDC q 1 0 0 1 612 773.2004395 cm /GS1 gs /Fm1 Do Q EMC endstream endobj 382 0 obj <>>>/Resources 385 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 65.791 -7.9 Td (This ) Tj 22.92 0 Td (label ) Tj 26.055 0 Td (may ) Tj 22.71 0 Td (not ) Tj 18.12 0 Td (be ) Tj 14.692 0 Td (the ) Tj 18.023 0 Td (latest ) Tj 29.595 0 Td (approved ) Tj 48.974 0 Td (by ) Tj 14.17 0 Td (FDA.
Altitude sickness
) Tj -281.05 -12 Td (For ) Tj 18.96 0 Td (current ) Tj 38.765 0 Td (labeling ) Tj 41.055 0 Td (information, ) Tj 61.25 0 Td (please ) Tj 34.707 0 Td (visit ) Tj 22.299 0 Td ( Tj ET endstream endobj 383 0 obj <>>>/Resources 387 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 0 -7.9 Td ( ) Tj ET endstream endobj 387 0 obj <> endobj 388 0 obj <> endobj 386 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 385 0 obj <> endobj 389 0 obj <> endobj 384 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 381 0 obj <> endobj 376 0 obj <>stream q 1 0 0 1 -8.535767 -1.877228 cm 0 0 612 792 re W n 1 0 0 1 8.535767 1.877228 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.4642 47.6228 Tm ( )Tj 19.25 -0.005 Td (8)Tj 0.0009 Tc -0.0009 Tw -19.25 54.94 Td [(on placebo. In the titration studies \(n=644\) \(with m)8.7 (o)0.9 (st patients eventually receiving 100 m)8.7 (g)0.9 (\), )]TJ 0.0011 Tc -0.0011 Tw sildenafil film tablet 0 -1.165 TD [(results were sim)8.9 (ilar. )]TJ 0 Tc 0 Tw -0.3 -1.165 Td ( )Tj 0.3 -17.655 Td ( )Tj ET q 1 0 0 1 -8.535767 -1.877228 cm 1 g 205.8 524.58 22.86 33.24 re f Q q 1 0 0 1 -8.535767 -1.877228 cm 205.26 524.58 24 33.78 re W n 0.961 w 1 j 1 J 205.8 557.82 22.86 -33.24 re S Q q 1 0 0 1 -8.535767 -1.877228 cm 1 g 262.5 524.58 22.86 87.12 re f Q q 1 0 0 1 -8.535767 -1.877228 cm 261.96 524.58 24 87.66 re W n 0.961 w 1 j 1 J 262.5 611.7 22.86 -87.12 re S Q q 1 0 0 1 -8.535767 -1.877228 cm 1 g 319.2 524.58 22.62 102.24 re f Q q 1 0 0 1 -8.535767 -1.877228 cm 318.66 524.58 23.76 102.78 re W n 0.961 w 1 j 1 J 319.2 626.82 22.62 -102.24 re S Q q 1 0 0 1 -8.535767 -1.877228 cm 1 g 375.66 524.58 22.86 113.34 re f Q q 1 0 0 1 -8.535767 -1.877228 cm 375.12 524.58 24 113.88 re W n 0.961 w 1 j 1 J 375.66 637.92 22.86 -113.34 re S Q q 1 0 0 1 -8.535767 -1.877228 cm 0.06 w 1 j 1 J q 1 0 0 1 189 662.88 cm 0 0 m 0 -138.3 l -2.4 -138.3 m 2.4 -138.3 l -2.4 -110.64 m 2.4 -110.64 l -2.4 -82.98 m 2.4 -82.98 l -2.4 -55.32 m 2.4 -55.32 l -2.4 -27.66 m 2.4 -27.66 l -2.4 0 m 2.4 0 l 0 -138.3 m 226.56 -138.3 l 0 -140.7 m 0 -135.84 l 56.7 -140.7 m 56.7 -135.84 l 113.4 -140.7 m 113.4 -135.84 l 169.86 -140.7 m 169.86 -135.84 l 226.56 -140.7 m 226.56 -135.84 l S Q Q BT /TT1 1 Tf 7.9369 0 0 7.9369 170.1442 520.4828 Tm (0)Tj -0.0119 Tc -0.544 3.485 Td (20)Tj 0 3.485 TD (40)Tj T* (60)Tj T* (80)Tj -0.544 3.485 Td (100)Tj -0.0421 Tc 4.233 -18.884 Td [(P)-40.4 (l)-31.6 (ac)-63.7 (eb)-30.2 (o)]TJ -0.0107 Tc 0.363 -1.3 Td [(n=4)-6.4 (6)1.2 (3)]TJ -0.0027 Tc 6.63 1.3 Td [(VIAG)-18.6 (R)-6.3 (A)]TJ -0.0107 Tc 0.005 Tw 0.544 -1.3 Td (25 mg)Tj 0 Tw -0.03 -1.308 Td [(n=2)-6.4 (1)1.2 (4)]TJ -0.0027 Tc 6.6 2.608 Td [(VIAG)-18.6 (R)-6.3 (A)]TJ -0.0107 Tc 0.005 Tw 0.544 -1.3 Td (50 mg)Tj 0 Tw -0.03 -1.308 Td [(n=3)-6.4 (9)1.2 (1)]TJ -0.0027 Tc 6.63 2.608 Td [(VIAG)-11.1 (R)-13.8 (A)]TJ -0.0109 Tc 0.0052 Tw 0.272 -1.3 Td (100 mg)Tj -0.0107 Tc 0 Tw 0.242 -1.308 Td [(n=3)-6.4 (8)1.2 (0)]TJ -0.0421 Tc 0.0364 Tw -12.927 -1.724 Td [(T)-73.8 (r)-41.7 (eat)-36.4 (m)-25.5 (en)-30.2 (t)-36.4 ( g)-30.2 (r)-41.7 (ou)-30.2 (p)]TJ 0.0019 Tc 0 Tw 0 7.9369 -7.9369 0 155.5642 518.3828 Tm [(Percentage pati)4.8 (ents reporti)4.8 (ng i)4.8 (m)3.3 (proveme)]TJ ET q 1 0 0 1 -8.535767 -1.877228 cm 156.78 520.2 9.18 148.26 re W n 1 0 0 1 8.535767 1.877228 cm BT 0 Tc 0 7.9369 -7.9369 0 155.5642 664.4228 Tm (n)Tj ET Q q 1 0 0 1 -8.535767 -1.877228 cm 1 g 209.4 559.98 28.86 13.68 re f Q BT -0.0119 Tc 7.9369 0 0 7.9369 203.0242 563.5028 Tm [(24)-7.6 (%)]TJ ET q 1 0 0 1 -8.535767 -1.877228 cm 1 g 377.82 638.64 21.9 14.16 re f Q BT 7.9369 0 0 7.9369 371.4442 642.6428 Tm (82%)Tj ET q 1 0 0 1 -8.535767 -1.877228 cm 1 g 322.56 627.54 21.9 14.22 re f Q BT 7.9369 0 0 7.9369 316.1842 631.6028 Tm (74%)Tj ET q 1 0 0 1 -8.535767 -1.877228 cm 1 g 266.34 613.14 21.9 14.16 re f Q BT 7.9369 0 0 7.9369 259.9642 617.1428 Tm [(63)-7.6 (%)]TJ /TT0 1 Tf 0 Tc 12 0 0 12 470.2042 467.0228 Tm ( )Tj 0.0011 Tc 0.0022 Tw 9 0 0 9 63.4642 458.6228 Tm ( )Tj 9 0 Td (Overall treatment p<0.0001 )Tj 0 Tc 0 Tw 12 0 0 12 63.4642 445.1828 Tm ( )Tj 0.0008 Tc 0.0006 Tw 10.98 0 0 10.98 203.9242 432.2228 Tm (Figure 4. )]TJ 0 Tc 0 Tw T* ( )Tj 0.0005 Tc -0.0005 Tw T* [(During 3 to 6 m)8.3 (onths of double-blind treatm)8.3 (e)-0.7 (nt or)]TJ 0.0008 Tc -0.0008 Tw 20.12 0 Td [( longer-term)8.6 ( \(1 year\), open-label studies, few )]TJ -20.12 -1.165 Td [(patients withdrew from)8.6 ( active treatm)8.6 (ent for any )]TJ 0.0005 Tc -0.0005 Tw 19.37 0 Td (reason, including lack of effectiveness.
- Sildenafil white was first approved by the FDA in 1998.
- It is marketed under various brand and generic names worldwide.
- The drug belongs to a class called phosphodiesterase inhibitors.
- It is effective for many men with both physical and psychological ED.
- Sildenafil white may also help treat pulmonary arterial hypertension.
- Some users report experiencing visual disturbances after taking it.
- The medication’s effects last approximately 4 to 6 hours.
- It is advisable to avoid alcohol when taking sildenafil white.
- Consumers should check for potential drug allergies before use.
- The pill's color and shape can vary depending on the manufacturer.
- Always consult a healthcare provider for appropriate use and dosing.
At the )Tj 0.0007 Tc -0.0007 Tw -19.37 -1.165 Td [(end of the long-term)8.5 ( study, 88% of patients re)2.2 (ported that VIAGRA im)8.4 (proved their erections.
- The term 'sildenafil white' often refers to unbranded, generic pills.
- It may be available online through various pharmacies and vendors.
- Users should verify the legitimacy of sildenafil sources to avoid fake products.
- This medication is not suitable for individuals with certain heart conditions.
- Sildenafil white is sometimes used recreationally for its euphoric effects.
- It may interact with certain antibiotics and antifungals, altering effectiveness.
- Patients should inform their doctor of all medications before use.
- The medication is not an aphrodisiac; it only facilitates erectile response.
- Overuse or misuse of sildenafil white can lead to serious health risks.
- The recommended maximum frequency is once per day unless advised otherwise.
- Consultation with a healthcare professional is essential prior to use.
)]TJ 0 Tc 0 Tw T* ( )Tj 0.0007 Tc -0.0007 Tw T* (Men with untreated ED had relatively low baseline scores for all aspects\ of sexual function )Tj T* [(m)8.4 (easured \(again using a 5-point scale\) in the IIEF.